This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aubé, J., Wolfe, M. S., Yantiss, R. K., Cook, S. M., and Takusagawa, F., 1992, Synthesis of enantiopure N-tert-butoxycarbonyl-2-aminocycloalkanones, Synth. Commun. 22(20):3003–3012.
Begley, D. J., 1996, The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system, J. Pharm. Pharmacol. 48:136–146.
Beinfeld, M. C., 1983, Cholecystokinin in the central nervous system: A minireview, Neuropeptides 3:411.
Bock, M. J., Mellin, E. C., Newton, R. C., Veber, D. F., Freedman, S. B., Smith, A. J., Patel, S., Kemp, J. A., Marshall, G. R., Fletcher, A. E., Chapman, K. L., Anderson, P. S., and Freidinger, R. M., 1994, Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogues with selectivity and water solubility, J. Med. Chem. 37:722–724.
Boden, P. R., Higginbottom, M., Hill, D. R., Horwell, D. C., Hughes, J., Rees, D. C., Roberts, E., Singh, L., Suman-Chauhan, N., and Woodruff, G. N., 1993, Cholecystokinin dipeptoid antagonists: Design, synthesis and anxiolytic profile of some novel CCK-A and CCK-B selective and mixed antagonists, J. Med. Chem. 36:552–565.
Bourin, M., Malinge, M., Vasar, E., and Bradwejn, J., 1996, Two faces of Cholecystokinin: Anxiety and schizophrenia, Fundam. Clin. Pharmacol. 10:116.
Bradwejn, J., and Koszycki, D., 1992, CCK receptors and panic attacks in man, in: Multiple Cholecystokinin Receptors in the CNS (C. T. Dourish, S. J. Cooper, S. D. Iversen, and L. I. Iverson, eds.), p. 121, Oxford University Press, London.
Bradwejn, J., Koszycki, D., and Meterissian, G., 1990, Cholecystokinin tetrapeptide in panic disorder, Can. J. Psychiatry 35:83.
Bradwejn, J., Koszycki, D., and Shriqui, C., 1991, Enhanced sensitivity to Cholecystokinin tetrapeptide in panic disorder, Arch. Gen. Psychiatry 48:603.
Bradwejn, J., Koszycki, D., Couetoux, du T. A., van Megan, H., den Boer, J Westenbergh, and Annable, L., 1994, The panicogenic effects of Cholecystokinin tetrapeptide are antagonized by L-365260, a central Cholecystokinin receptor antagonist, in patients with panic disorder, Arch. Gen. Psychiatry 51:486.
Bradwejn, J., Koszycki, D., Paradis, M., Reece, P., Hinton, J., and Sedman, A., 1995, Effect of CI-988 on Cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers, Biol. Psychiatry 38:742.
Chen, I.-W., Dorley, J. M., Ranjit, H. G., Pitzenberger, S. M., and Lin, J. H., 1992, Physiological disposition and metabolism of L-365,260, a potent antagonist of brain Cholecystokinin receptor, in laboratory animals, Drug Metab. Dispos. 20:390–395.
Cook, J., Siedlik, P., and Reece, P., 1995, Effect of Maalox TC on CI-988 pharmacokinetics, Pharm. Res. 12(9):S390.
Crawley, J. N., 1989, Micro-injection of Cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion, Synapse 3:34336.
D’Amato, M., Makovec, F., and Rovati, L., 1994, Potential clinical applications of CCK-A receptor antagonists in gastroenterology, Drug News Perspect. 7(2):87–95.
Dethloff, L. A., and Hinton, J. P., 1997, Toxico kinetic comparison of a CCK-B / gastrin receptor antagonist given orally and intravenously. Drug Dev. Res. 40:292–298.
De Weerth, A., Pisegna, J. R., Hupi, K., and Wank, S. A., 1993, Molecular cloning, functional expression and chromosomal localization of the human Cholecystokinin type A receptor, Biochem. Biophys. Res. Commun. 194:811.
DiMassi, J. A., 1995, Success rates for new drugs entering clinical testing in the United States, Clin. Pharmacol. Ther. 58:1–14.
Dourish, C. T, and Hill, D. R., 1987, Classification and function of CCK receptors, Trends Pharm. Sci. 8:207.
Doyle, J. W., Wolfe, M., and McGuigan, J. E., 1984, Hepatic clearance of gastrin and cholecystokinin peptides, Gastroenterlogy 87:60–68.
Dubroeucq, M. C., Guyon, C., Manfre, F., Capet, M., Barreau, M., and Betrand, P., 1994, Evaluation of brain penetration of CCK-B antagonists, Ann. N. Y. Acad. Sci. 713:377–379.
Feng, R., Hinton, J. P., Hoffman, K., Parker, T. D., and Wright, D. S., 1993, Pharmacokinetics and oral bioavailability of CI-988 ester prodrugs in Wistar rats, Pharm. Res. 10(10):S346.
Freedman, S. B., Patel, S., Smith, A. J., Chapman, K., Fletcher, A., Kemp, J. A., Marshall, G. R., Hargreaves, R. J., Scholey, K., Mellin, E. C., DiPardo, R. M., Bock, M. G., and Freidinger, R. M., 1994, A second generation of non-peptide cholecystokinin receptor antagonists and their therapeutic potential, Ann. N.Y. Acad. Sci. 713:312–318.
Gores, G. J., LaRusso, N. F, and Miller, L. J., 1986a, Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction, Am. J. Physiol. 250(Gastrointest. Liver Physiol. 13):G344–G349.
Gores, G. J., Miller, L. J., and LaRusso, N. F., 1986b, Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion, Am. J. Physiol. 250(Gastrointest. Liver Physiol. 13):G350–G356.
Hansch, C., Bjorkroth, J. P., and Leo, A., 1987, Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design, J. Pharm. Sci. 76:663–687.
Hinton, J. P., Rutkowski, K., Johnson, E. L., and Wright, D. S., 1991, Single dose pharmacokinetics and absolute bioavailability of the anxiolytic CI-988 in fasted and fed cynomolgus monkeys, Pharm. Res. 8(10):S267.
Hinton, J., Hoffmann, G., Poisson, A., Klemisch, W., and Wright, D. S., 1993, Mass balance and disposition of [14C]CI-988 in cynomolgus monkeys, Pharm. Res. 10(10):S330.
Hinton, J. P., Jennings, K., Johnson, E. L., and Wright, D. S., 1995a, A sensitive HPLC assay for the cholecystokinin-B antagonist, CI-988, in human and monkey plasma, Biomed. Chrom. 9:94–97.
Hinton, J. P., Jennings, K., Wright, D. S., Reece, P. A., and Sedman, A. J., 1995b, A food-effect study of CI-988 capsules and solution in healthy volunteers, Pharm. Res. 12(9):S420.
Hinton, J. P., Pablo, J., Bjorge, S., Hoffman, K., Jennings, K., and Wright, D. S., 1996, Three complementary liquid chromatographic methods for determination of the peptoid cholecystokinin-B antagonist, CI-988, in rat plasma, J. Pharm. Biomed. Anal. 14:815–824.
Holladay, M. W., Bennett, M. J., Tufano, M. D., Lin, C. W., Asin, K. E., Witte, D. G., Miller, T. R., Bianchi, B. R., Nikkel, A. L., Bednarz, L., and Nadzan, A. M., 1992, Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro and appetite suppression in vivo. J. Med. Chem. 35:2919.
Horwell, D. C., Hughes, J., Hunter, J. C., Pritchard, M. C., Richardson, R. S., Roberts, E., and Woodruff, G. N., 1991, Rationally designed “dipeptoid” analogueues of CCK. Methyltryptophan derivative as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties, J. Med. Chem. 34:404–414.
Hughes, J., Boden, P., Costall, B., Domeney, A., Kelly, E., Horwell, D. C., Hunter, J. C., Pinock, R. D., and Woodruff, G. N., 1990, Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity, Proc. Natl. Acad. Sci. USA 87:6728.
Hunter, E. B., Powers, S. P., Kost, L. J., Pinon, D. I., Miller, L. J., and LaRusso, N. F., 1990, Physiochemical determinants in hepatic extraction of small peptides, Hepatology 12(l):76–82.
Innis, R. B., and Snyder, S. H., 1980, Distinct cholecystokinin receptors in brain and pancreas, Proc. Natl. Acad. Sci. USA 77:6917.
Larsson, L.-I., and Rehfeld, J. F., 1979, Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res. 165:201.
Lee, Y. M., Beinborn, M., McBride, E. W., Lu, M., Kolakowski, L. F, and Kopin, A. S., 1993, The human brain cholecystokinin-B / gastrin receptor, J. Biol. Chem. 268:8164.
Overman, L. E., and Sugai, S., 1985, A convenient method for obtaining trans-2-amino cyclohexanol and trans-2-aminocyclopentanol in enantiomerically pure form, J. Org. Chem. 50:4154–4155.
Patel, S., Chapman, K. L., Heald, A., Smith, A. J., and Freedman, S. B., 1994, Measurement of central nervous system activity of systemically administered CCK-B receptor antagonists by ex vivo binding, Eur. J. Pharmacol. 253:237–244.
Prentis, R. A., Lis, Y., and Walker, S. R., 1988, Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964–1985), Br. J. Clin. Pharmacol. 25:387–396.
Rehfeld, J. R, and Nielsen, F. C., 1995, Molecular forms and regional distribution of cholecystokinin in the central nervous system, in: Cholecystokinin and Anxiety: From Neuron to Behavior (J. Bradwejn and E. Vasar, eds.), pp. 33–56, RG Landes Company, Austin, TX.
Rehfeld, J. F., Goltermann, N., Larsson, L.-I., Emson, P. M., and Lee, C. M., 1979, Gastrin and cholecystokinin in central and peripheral neurons, Fed. Proc. 38:2325.
Showell, G. A., Bourrain, S., Neduvelil, J. G., Fletcher, S. R., Baker, R., Watt, A. P., Fletcher, A. E., Freedman, S. B., Kemp, J. A., Marshall, G. R., Patel, S., Smith, A. J., and Matassa, V. G., 1994, High affinity and potent, water soluble 5-amino-1,4-benzodiazepine CCK-B/gastrin receptor antagonists containing a cationic solubilizing group, J. Med. Chem. 37:719–721.
Singh, L., Field, M. J., Hughes, J., Menzies, R., Oles, R. J., Vass, C. A., and Woodruff, G. N., 1991, The behavioral properties of CI-988, a selective cholecystokinin B receptor antagonist, Br. J. Pharmacol. 104(1):239–245.
Trivedi, B. K., 1994a, Ligands for cholecystokinin receptors: Recent developments, Curr. Opin. Ther. Patents 4(l):31–44.
Trivedi, B. K., 1994b, Cholecystokinin receptor antagonists: Current status, Curr. Med. Chem. 1:313–327.
Trivedi, B. K., Padia, J. K., Holmes, A., Rose, S., Wright, D. S., Hinton, J. P., Pritchard, M. C., Eden, J. M., Kneen, C., Webdale, L., Suman-Chauhan, N., Boden, P., Singh, L., and Hill, D., 1998, Second generation “dipeptoid” CCK-B antagonists: Identification and development of CI-1015 with an improved pharmacokinetic profile, J. Med. Chem. 41(1):38–45.
Voigt, M., Wang, R. Y., and Westfall, T. C., 1986, Cholecystokinin octapeptides alter the release of endogenous dopamine neurons in vitro, J. Pharmacol. Exp. Ther. 237:147.
Wang, Y.-M., Hinton, J. P., Atherton, J. P., and Wright, D. S., 1995, Pharmacokinetics and bioavailability of PD 145942 in cynomolgus monkeys, Pharm. Res. 12(9):S426.
Wank, S. A., Pisegna, J. R., and DeWeerth, A. 1992, Brain and gastrointestinal cholecystokinin receptor family and functional expression, Proc. Natl. Acad. Sci. USA 89:8691.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Trivedi, B.K., Hinton, J.P. (2002). CI-1015. In: Borchardt, R.T., Freidinger, R.M., Sawyer, T.K., Smith, P.L. (eds) Integration of Pharmaceutical Discovery and Development. Pharmaceutical Biotechnology, vol 11. Springer, Boston, MA. https://doi.org/10.1007/0-306-47384-4_21
Download citation
DOI: https://doi.org/10.1007/0-306-47384-4_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-45743-2
Online ISBN: 978-0-306-47384-5
eBook Packages: Springer Book Archive